Targets › PPARA
11 programs from 10 companies in 30 trials: 15 Phase 3, 10 Phase 2, 3 Phase 1, 2 Phase 4; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Ligand-activated transcription factor. Key regulator of lipid metabolism. (UniProt, Q07869)
Open in Phaseline: the race on PPARA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kowa Company | Pemafibrate Peroxisome proliferator-activated receptor alpha agonist | PPARA | Phase 4 | Hypercholesterolemia | Jul 2027 |
| Ipsen | Elafibranor Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist | PPARA, PPARD | Phase 3 | Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis | Dec 2026 |
| Zydus Therapeutics | Saroglitazar Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist | PPARA, PPARG | Phase 3 | Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver Disease | Dec 2026 |
| Xijing Hospital of Digestive Diseases | Fenofibrate Peroxisome proliferator-activated receptor alpha agonist | PPARA | Phase 3 | Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC) | Apr 2027 |
| Inventiva Pharma | Lanifibranor (IVA337) Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Bezafibrate Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 3 | BPC | Dec 2027 |
| The First Affiliated Hospital of Xiamen University | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia | Dec 2026 |
| RDC Clinical | Oleoylethanolamide (Trpti) Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy Volunteers | Feb 2027 |
| RDC Clinical | Palmitoylethanolamide (PEA) Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual Dizziness | Feb 2027 |
| Medical University of Vienna | Fenofibric acid Peroxisome proliferator-activated receptor alpha agonist | PPARA | Phase 2 | Medulloblastoma Recurrent | Apr 2030 |
| Shanghai Jiao Tong University School of Medicine | Chiglitazar Peroxisome proliferator-activated receptor agonist | PPARG, PPARA, PPARD | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Dec 2030 |
Primary Biliary Cholangitis (7) Primary Biliary Cholangitis (PBC) (4) Primary Biliary Cirrhosis (2) Primary Sclerosing Cholangitis (2) BPC (2) Sleep Disorder (Disorder) (2) Hypercholesterolemia (1) Hepatic Impairment (1) Cholestatic Liver Disease (1) Medulloblastoma Recurrent (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1)
small molecule (8), mixed (1)
RDC Clinical (2) Ipsen (1) Xijing Hospital of Digestive Diseases (1) Assistance Publique - Hôpitaux de Paris (1) Kowa Company (1) Zydus Therapeutics (1) Medical University of Vienna (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) Inventiva Pharma (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.